Recombinant Hypoallergenic Cat Allergy Vaccines
Allergy · 2025
DOI: 10.1111/all.16542 ↗Kurz gefasst
Fachartikel in der Zeitschrift Allergy, 2025. Verfasst von Daria Trifonova und 17 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pathophysiology and Allergy Research, Division of Immunopathology, Center for Pathophysiology, Infectiology, and Immunology, Medical Un…. Hauptthemen laut MEDLINE: Vaccines, Synthetic, Hypersensitivity, Cats, Allergens. Die Arbeit wurde bisher 11-mal zitiert (Crossref) und nennt 57 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Worg Pharmaceuticals, Danube Allergy Research Cluster of the Country of Lower Austria, Russian Science Foundation.
Abstract (Originalsprache)
Background
Molecular forms of allergen‐specific immunotherapy (AIT) for cat allergy are needed. Fel d 1, Fel d 4, and Fel d 7 are the most important cat allergens.
Methods
IgE epitopes of Fel d 4 and Fel d 7 were mapped by blocking allergic patients' IgE binding with allergen peptide‐specific antisera. Five recombinant fusion proteins (PreS‐Cat 1‐PreS‐Cat 5) each containing hepatitis B virus (HBV)‐derived PreS as an immunological carrier and non‐allergenic peptides from the IgE binding sites of Fel d 1, Fel d 4, and Fel d 7 were expressed in Escherichia coli , purified, and characterized by mass spectrometry, circular dichroism (CD), and size exclusion chromatography. ImmunoCAP and basophil activation experiments demonstrated the hypoallergenic activity of PreS‐Cat 1–5. The ability of PreS‐Cat 1–5 to induce IgE‐blocking antibodies in rabbits was compared to three licensed allergen extract‐based AIT vaccines. PreS‐Cat 1‐5‐specific IgG antibodies were tested for inhibition of allergen‐specific IgE binding and specific basophil activation. T cell activation and induction of specific cytokine secretion by PreS‐Cat proteins were compared with cat allergens in PBMC cultures.
Results
Recombinant hypoallergenic, biochemically and structurally defined PreS‐Cat 1–5 were obtained. Two subcutaneous immunizations of rabbits with PreS‐Cat 1–5 induced equal (Fel d 1) or better (Fel d 4 and Fel d 7) antibodies (PreS‐Cat 5 > PreS‐Cat 1 > PreS‐Cat 3) blocking allergic patients' IgE binding to cat allergens than six to fifteen immunizations with allergen extract‐based vaccines. PreS‐Cat‐specific antibodies strongly inhibited specific basophil activation. PreS‐Cat 5 > PreS‐Cat 1 induced significantly more IL‐10 in cultured PBMCs from cat allergic patients than cat allergens.
Conclusions
PreS‐Cat 5 and PreS‐Cat 1 are highly promising molecular vaccine candidates for AIT of cat allergy, combining Fel d 1‐, Fel d 4‐, and Fel d 7‐peptides in single PreS fusion proteins.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Pathophysiology and Allergy Research, Division of Immunopathology, Center for Pathophysiology, Infectiology, and Immunology, Medical University of Vienna, Vienna, Austria.
- LIFE Improvement by Future Technologies (LIFT) Center, Skolkovo, Moscow, Russia.
- Department of Medicine Solna, Division of Immunology and Respiratory Medicine and Center for Molecular Medicine, Karolinska Institutet and University Hospital, Stockholm, Sweden.
- Therapeutic Immune Design Unit, Department of Clinical Neuroscience, Karolinska Institutet, Stockholm, Sweden.
- Center for Molecular Allergology, Karl Landsteiner University for Healthcare Sciences, Krems, Austria.
- Institute of Molecular Biosciences, BioTechMed Graz, University of Graz, Graz, Austria.
ORCID-Profile: Marianne van Hage, Hans Grönlund, Walter Keller, Rudolf Valenta
Förderung
- Worg Pharmaceuticals
- Danube Allergy Research Cluster of the Country of Lower Austria
- Russian Science Foundation
- Region Stockholm (ALF Project)
- Swedish Asthma and Allergy Association's Research Foundation
- Swedish Heart-Lung Foundation
Zitieren
APA
Trifonova, D., Curin, M., Focke-Tejkl, M., Liu, Z., Borochova, K., Gattinger, P., van Hage, M., Grönlund, H., Kiss, R., Huang, H. J., Keller, W., Riabova, K., Karsonova, A., Kundi, M., Tulaeva, I., Fomina, D., Karaulov, A., & Valenta, R. (2025). Recombinant Hypoallergenic Cat Allergy Vaccines. Allergy. https://doi.org/10.1111/all.16542
Vancouver
Trifonova D, Curin M, Focke-Tejkl M, Liu Z, Borochova K, Gattinger P, et al. Recombinant Hypoallergenic Cat Allergy Vaccines. Allergy. 2025. doi:10.1111/all.16542
BibTeX
@article{Trifonova2025,
author = {Trifonova, Daria and Curin, Mirela and Focke-Tejkl, Margarete and Liu, Zicheng and Borochova, Kristina and Gattinger, Pia and van Hage, Marianne and Grönlund, Hans and Kiss, Renata and Huang, Huey-Jy and Keller, Walter and Riabova, Ksenja and Karsonova, Antonina and Kundi, Michael and Tulaeva, Inna and Fomina, Daria and Karaulov, Alexander and Valenta, Rudolf},
title = {Recombinant Hypoallergenic Cat Allergy Vaccines},
journal = {Allergy},
year = {2025},
doi = {10.1111/all.16542}
}
EUVIMED